{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:48:14Z","timestamp":1791863294093,"version":"4.3.4"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP25ek0109811"],"award-info":[{"award-number":["JP25ek0109811"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP22ek0109616"],"award-info":[{"award-number":["JP22ek0109616"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP23bm1423002"],"award-info":[{"award-number":["JP23bm1423002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP22bm0804003"],"award-info":[{"award-number":["JP22bm0804003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP25wm0625519"],"award-info":[{"award-number":["JP25wm0625519"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP23kk0305024"],"award-info":[{"award-number":["JP23kk0305024"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21wm0425009"],"award-info":[{"award-number":["JP21wm0425009"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP23bm1123046"],"award-info":[{"award-number":["JP23bm1123046"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020050","name":"Japan Intractable Diseases Research Foundation","doi-asserted-by":"publisher","award":["2024A04"],"award-info":[{"award-number":["2024A04"]}],"id":[{"id":"10.13039\/100020050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008664","name":"Ono Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008664","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP21H05278"],"award-info":[{"award-number":["JP21H05278"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP26H02431"],"award-info":[{"award-number":["JP26H02431"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP26K10434"],"award-info":[{"award-number":["JP26K10434"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP25H00007"],"award-info":[{"award-number":["JP25H00007"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP22K15736"],"award-info":[{"award-number":["JP22K15736"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003844","name":"Inamori Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003844","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008731","name":"The Nakatomi Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regenerative Therapy"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.reth.2026.101150","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T21:24:41Z","timestamp":1781558681000},"page":"101150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Therapeutic frontiers in ALS: iPSC-based drug discovery, cell therapy, and gene therapy\u2014Advances through 2026"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0022-9529","authenticated-orcid":false,"given":"Satoru","family":"Morimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0903-3891","authenticated-orcid":false,"given":"Shinichi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7482-5935","authenticated-orcid":false,"given":"Hideyuki","family":"Okano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.reth.2026.101150_bib1","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1001\/jamaneurol.2022.0901","article-title":"Efficacy and safety of ultrahigh-dose methylcobalamin in early-stage amyotrophic lateral sclerosis: a randomized clinical trial","volume":"79","author":"Oki","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.reth.2026.101150_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.celrep.2014.03.019","article-title":"Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons","volume":"7","author":"Wainger","year":"2014","journal-title":"Cell Rep"},{"key":"10.1016\/j.reth.2026.101150_bib3","first-page":"1218","article-title":"Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons","volume":"321","author":"Dimos","year":"2008","journal-title":"Science (1979)"},{"key":"10.1016\/j.reth.2026.101150_bib4","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/s41593-021-01006-0","article-title":"Answer ALS, a large-scale resource for sporadic and familial ALS combining clinical and multi-omics data from induced pluripotent cell lines","volume":"25","author":"Baxi","year":"2022","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.reth.2026.101150_bib5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41593-025-02118-7","article-title":"Large-scale drug screening in iPSC-derived motor neurons from sporadic ALS patients identifies a potential combinatorial therapy","volume":"29","author":"Bye","year":"2026","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.reth.2026.101150_bib6","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1038\/s41591-018-0140-5","article-title":"Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent","volume":"24","author":"Fujimori","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.reth.2026.101150_bib7","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.stem.2023.04.017","article-title":"Phase 1\/2a clinical trial in ALS with ropinirole, a drug candidate identified by iPSC drug discovery","volume":"30","author":"Morimoto","year":"2023","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.reth.2026.101150_bib8","doi-asserted-by":"crossref","DOI":"10.1111\/jnc.70183","article-title":"Ropinirole functions through a dopamine receptor D2-Independent mechanism to ameliorate amyotrophic lateral sclerosis phenotypes in TARDBP-mutant iPSC-Derived motor neurons","volume":"169","author":"Asano","year":"2025","journal-title":"J Neurochem"},{"key":"10.1016\/j.reth.2026.101150_bib9","doi-asserted-by":"crossref","first-page":"eaaf3962","DOI":"10.1126\/scitranslmed.aaf3962","article-title":"The Src\/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis","volume":"9","author":"Imamura","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.reth.2026.101150_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101707","article-title":"Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): a multicentre, open-label, dose-escalation phase 1 trial","volume":"53","author":"Imamura","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.reth.2026.101150_bib11","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1001\/jamaneurol.2020.4300","article-title":"Effect of ezogabine on cortical and spinal motor neuron excitability in amyotrophic lateral sclerosis: a randomized clinical trial","volume":"78","author":"Wainger","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.reth.2026.101150_bib12","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/mus.27472","article-title":"A randomized placebo\u2010controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis","volume":"65","author":"Cudkowicz","year":"2022","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.reth.2026.101150_bib13","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/ana.25302","article-title":"Repeated intrathecal mesenchymal stem cells for amyotrophic lateral sclerosis","volume":"84","author":"Oh","year":"2018","journal-title":"Ann Neurol"},{"key":"10.1016\/j.reth.2026.101150_bib14","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1038\/s41591-022-01956-3","article-title":"Transplantation of human neural progenitor cells secreting GDNF into the spinal cord of patients with ALS: a phase 1\/2a trial","volume":"28","author":"Baloh","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.reth.2026.101150_bib15","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/s41591-022-01983-0","article-title":"A combined stem-cell-gene therapy strategy for ALS","volume":"28","author":"Okano","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.reth.2026.101150_bib16","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.molmed.2022.09.009","article-title":"Transplantation of neural progenitor cells into the human CNS","volume":"28","author":"Okano","year":"2022","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.reth.2026.101150_bib17","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12967-023-03903-3","article-title":"Safety and efficacy of first-in-man intrathecal injection of human astrocytes (AstroRx\u00ae) in ALS patients: phase I\/IIa clinical trial results","volume":"21","author":"Gotkine","year":"2023","journal-title":"J Transl Med"},{"key":"10.1016\/j.reth.2026.101150_bib18","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.89530","article-title":"ALS patients' regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity","volume":"2","author":"Beers","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.reth.2026.101150_bib19","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000465","article-title":"Expanded autologous regulatory T-lymphocyte infusions in ALS","volume":"5","author":"Thonhoff","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.reth.2026.101150_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1415106","article-title":"A phase 1 proof-of-concept study evaluating safety, tolerability, and biological marker responses with combination therapy of CTLA4-Ig and interleukin-2 in amyotrophic lateral sclerosis","volume":"15","author":"Thonhoff","year":"2024","journal-title":"Front Neurol"},{"key":"10.1016\/j.reth.2026.101150_bib21","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(25)00262-4","article-title":"Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial","volume":"405","author":"Bensimon","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.reth.2026.101150_bib22","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2025.01.003","article-title":"Pluripotent stem-cell-derived therapies in clinical trial: a 2025 update","volume":"32","author":"Kirkeby","year":"2025","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.reth.2026.101150_bib23","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","article-title":"Trial of antisense oligonucleotide tofersen for SOD1 ALS","volume":"387","author":"Miller","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.reth.2026.101150_bib24","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1007\/s13311-022-01237-4","article-title":"Design of a randomized, placebo-controlled, phase 3 trial of tofersen initiated in clinically presymptomatic SOD1 variant carriers: the ATLAS study","volume":"19","author":"Benatar","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.reth.2026.101150_bib25","doi-asserted-by":"crossref","first-page":"6424","DOI":"10.1016\/j.cell.2025.07.045","article-title":"Molecular impact of antisense oligonucleotide therapy in C9orf72-associated ALS","volume":"188","author":"McEachin","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.reth.2026.101150_bib26","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S1474-4422(24)00517-9","article-title":"Amyotrophic lateral sclerosis caused by FUS mutations: advances with broad implications","volume":"24","author":"Moens","year":"2025","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.reth.2026.101150_bib27","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41591-021-01615-z","article-title":"Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis","volume":"28","author":"Korobeynikov","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.reth.2026.101150_bib28","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41593-018-0300-4","article-title":"ALS-Implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair","volume":"22","author":"Klim","year":"2019","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.reth.2026.101150_bib29","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41593-018-0293-z","article-title":"Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration","volume":"22","author":"Melamed","year":"2019","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.reth.2026.101150_bib30","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41586-022-04436-3","article-title":"TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A","volume":"603","author":"Brown","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.reth.2026.101150_bib31","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1016\/j.ymthe.2025.05.010","article-title":"RNAi-mediated silencing of SOD1 profoundly extends survival and functional outcomes in ALS mice","volume":"33","author":"Weiss","year":"2025","journal-title":"Mol Ther"},{"key":"10.1016\/j.reth.2026.101150_bib32","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMoa2005056","article-title":"SOD1 suppression with adeno-associated virus and MicroRNA in familial ALS","volume":"383","author":"Mueller","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.reth.2026.101150_bib33","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/s42003-021-01942-4","article-title":"Efficacy and long-term safety of CRISPR\/Cas9 genome editing in the SOD1-linked mouse models of ALS","volume":"4","author":"Deng","year":"2021","journal-title":"Commun Biol"},{"key":"10.1016\/j.reth.2026.101150_bib34","doi-asserted-by":"crossref","first-page":"6286","DOI":"10.1038\/s41467-022-33332-7","article-title":"CRISPR\/Cas9-mediated excision of ALS\/FTD-causing hexanucleotide repeat expansion in C9ORF72 rescues major disease mechanisms in vivo and in vitro","volume":"13","author":"Meijboom","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.reth.2026.101150_bib35","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.ymthe.2020.01.005","article-title":"Treatment of a mouse model of ALS by in vivo base editing","volume":"28","author":"Lim","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.reth.2026.101150_bib36","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.reth.2019.07.002","article-title":"Ropinirole hydrochloride remedy for amyotrophic lateral sclerosis \u2013 protocol for a randomized, double-blind, placebo-controlled, single-center, and open-label continuation phase I\/IIa clinical trial (ROPALS trial)","volume":"11","author":"Morimoto","year":"2019","journal-title":"Regen Ther"}],"container-title":["Regenerative Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235232042600091X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235232042600091X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:25:22Z","timestamp":1791861922000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S235232042600091X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":36,"alternative-id":["S235232042600091X"],"URL":"https:\/\/doi.org\/10.1016\/j.reth.2026.101150","relation":{},"ISSN":["2352-3204"],"issn-type":[{"value":"2352-3204","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic frontiers in ALS: iPSC-based drug discovery, cell therapy, and gene therapy\u2014Advances through 2026","name":"articletitle","label":"Article Title"},{"value":"Regenerative Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reth.2026.101150","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier BV on behalf of The Japanese Society for Regenerative Medicine.","name":"copyright","label":"Copyright"}],"article-number":"101150"}}